Are you Dr. Jensen?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Connect with colleagues in the same hospital or clinic
You already have 46 invites waiting! - Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
1500 Duarte Rd
Mob 4th Floor
Duarte, CA 91010Phone+1 626-301-8993- Is this information wrong?
Summary
- Dr. Michael Jensen, MD is a pediatric hematologist/oncologist in Duarte, California.
Education & Training
University of WashingtonFellowship, Pediatric Hematology/Oncology, 1993 - 1996
Children's Hospital-OaklandResidency, Pediatrics, 1990 - 1993
Perelman School of Medicine at the University of PennsylvaniaClass of 1990
Publications & Presentations
PubMed
- 52 citationsIntraventricular B7-H3 CAR T Cells for Diffuse Intrinsic Pontine Glioma: Preliminary First-in-Human Bioactivity and Safety.Nicholas A Vitanza, Ashley L Wilson, Wenjun Huang, Kristy Seidel, Christopher Brown, Joshua A Gustafson, Jason K Yokoyama, Adam J Johnson, Blake A Baxter, Ryan W Konin...> ;Cancer Discovery. 2023 Jan 9
- 2 citationsHuman CD19-specific switchable CAR T-cells are efficacious as constitutively active CAR T-cells but cause less morbidity in a mouse model of human CD19malignancy.Christopher A Pennell, Heather Campbell, Meghan D Storlie, Sara Bolivar-Wagers, Mark J Osborn, Yosef Refaeli, Michael Jensen, Sophie Viaud, Travis S Young, Bruce R Blazar> ;Journal for Immunotherapy of Cancer. 2022 Dec 1
- 9 citationsFGFR4-Targeted Chimeric Antigen Receptors Combined with Anti-Myeloid Polypharmacy Effectively Treat Orthotopic Rhabdomyosarcoma.Peter M Sullivan, Rajesh Kumar, Wei Li, Virginia Hoglund, Lingyan Wang, Yue Zhang, Megan Shi, Dusan Beak, Adam Cheuk, Michael C Jensen, Javed Khan, Dimiter S Dimitrov,...> ;Molecular Cancer Therapeutics. 2022 Oct 7
- Join now to see all
Press Mentions
City of Hope Researchers Achieve Remission Using CAR-T Cell Therapy for Aggressive Brain TumorsDecember 28th, 2016
Grant Support
- Targeted Therapy Of All With Gene-Modified Central Memory T CellsNational Cancer Institute2009–2011
- Clinical Trial: Pilot/Feasibility Study To Evaluate The Safety Of CellularNational Center For Research Resources2008
- Cellular Immunotherapy For Follicular Lymphoma Using CD19- Specific T-CellsNational Cancer Institute2007–2008
- Pilot/Feasibility Study To Evaluate The Safety Of CellularNational Center For Research Resources2007
- Cellular Immunotherapy Of Glioblastoma Multiforme Using AnNational Center For Research Resources2007
- Pilot Feasibility And Safety Study Of Cellular Immunotherapy For Recurrent/RefNational Center For Research Resources2005–2007
- Glioma Immunotherapy Usingengineered T-CellsNational Cancer Institute2005–2006
- CD19 Specific Immunotherapy For Follicular LymphomaNational Cancer Institute2004–2006
- Pilot Feasibility And Safety Study Of Cell ImmunotherapyNational Center For Research Resources2004
- Glioma Immunotherapy Using Engineered T-CellsNational Cancer Institute2004
- Cellular Immunotherapy For Neuroblastoma With CTL ClonesNational Cancer Institute2001–2002
- Targeting Malignant B Cells In Lymphoma And LeukemiaNational Cancer Institute2000–2002
- Core--Metabolic Human Studies--ObesityNational Institute Of Diabetes And Digestive And Kidney Diseases1996
